← All stocks

Acrivon Therapeutics, Inc.

ACRV Net buying

CIK 0001781174 #4343 in the set updated 17 Sep 2026

Bought (12 mo)

$114.34K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$39.81K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$39.81K

9 of 9 sales

Net

+$74.53K

+$74.53K against sales at will

By person

17 insiders · 12 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Blume-Jensen Peter

President and CEO

$82.12K (1)

$34.41K (3)

+$47.71K

2,615,911

6.10%

$5.77M

−4.5%

Devroe Eric

Chief Operating Officer

$17.22K (1)

$1.21K (1)

+$16.00K

146,349

0.3415%

$322.90K

+113.7%

Levy Adam D.

Chief Financial Officer

$15.00K (1)

$1.79K (1)

+$13.21K

66,008

0.1540%

$145.64K

+395.7%

Miller Mary

Chief Legal Officer

—

$1.38K (2)

−$1.38K

82,009

0.1914%

$180.94K

+110.5%

Gamelin Erick

Chief Development Officer

—

$804.00 (1)

−$804.00

52,592

0.1227%

$116.04K

+202.9%

Peterson Katharine

Chief Accounting Officer

—

$203.01 (1)

−$203.01

18,033

0.0421%

$39.79K

+289.1%

PERCEPTIVE ADVISORS LLC entity

10% owner

—

3,104,139

7.24%

$6.85M

−42.1%

Mirza Mansoor Raza

Chief Medical Officer

—

38,817

0.0906%

$85.65K

—

Levin Michaela

Chief Business Officer

—

30,000

0.0700%

$66.19K

—

Holm-Jorgensen Rasmus

Chief Financial Officer

—

26,088

0.0609%

$57.56K

−3.0%

RA CAPITAL MANAGEMENT, L.P. entity

Director

—

9,366

0.0219%

$20.67K

—

DiRocco Derek

Director

—

9,366

0.0219%

$20.67K

—

Palani Santhosh

Director

—

9,366

0.0219%

$20.67K

—

Magovcevic-Liebisch Ivana

Director

—

9,366

0.0219%

$20.67K

—

TOMSICEK MICHAEL JOHN

Director

—

9,366

0.0219%

$20.67K

—

Shacham Sharon

Director

—

9,366

0.0219%

$20.67K

—

BAUM CHARLES M

Director

—

9,366

0.0219%

$20.67K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Blume-Jensen Peter

25 Aug 2026

President and CEO

Sell

14,036

$2.21

$30.97K

Blume-Jensen Peter

18 Aug 2026

President and CEO

Sell indirect

484

$2.01

$972.84

Blume-Jensen Peter

18 Aug 2026

President and CEO

Sell

1,229

$2.01

$2.47K

Devroe Eric

18 Aug 2026

Chief Operating Officer

Sell

604

$2.01

$1.21K

Gamelin Erick

18 Aug 2026

Chief Development Officer

Sell

400

$2.01

$804.00

Miller Mary

18 Aug 2026

Chief Legal Officer

Sell

185

$2.01

$371.85

Peterson Katharine

18 Aug 2026

Chief Accounting Officer

Sell

101

$2.01

$203.01

Levy Adam D.

4 Aug 2026

Chief Financial Officer

Sell

1,142

$1.57

$1.79K

Miller Mary

21 Jul 2026

Chief Legal Officer

Sell

573

$1.76

$1.01K

Levy Adam D.

14 Jan 2026

Chief Financial Officer

Buy

8,832

$1.70

$15.00K

Blume-Jensen Peter

14 Jan 2026

President and CEO

Buy

49,000

$1.68

$82.12K

Devroe Eric

13 Jan 2026

Chief Operating Officer

Buy

10,000

$1.72

$17.22K

What was left out

Form 4 filings counted 64

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 14

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 9

Transactions with no price 0

Shares from compensation/vesting 4,615,819

History held since 16 Nov 2022